The balance between intrahepatic IL-17+ T cells and Foxp3+ regulatory T cells plays an important role in HBV-related end-stage liver disease

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Niu, Yinghua ^a   Liu, Hongli ^a   Yin, Donglin ^a   Yi, Ruitian ^a   Chen, Tianyan ^a   Xue, Hong'an ^a   Zhang, Shulin ^a   Lin, Shumei ^a   Zhao, Yingren ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PERFORIN;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; CELL FUNCTION; CELL POPULATION; CHRONIC HEPATITIS; CHRONIC LIVER FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; INFLAMMATORY CELL; LIVER CELL; LYMPHOCYTIC INFILTRATION; MALE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; END STAGE LIVER DISEASE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-17; LIVER; MALE; MIDDLE AGED; PERFORIN; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 80051802248     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-47     Document Type: Article

References (30)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403. 10.1016/S1473-3099(02)00315-8, 12127351.
2. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002, 2:43-50. 10.1016/S1473-3099(01)00172-4, 11892495.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001, 34:1225-41. 10.1053/jhep.2001.29401, 11732013.
4. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-9. 10.1126/science.284.5415.825, 10221919.
5. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77:68-76. 10.1128/JVI.77.1.68-76.2003, 140637, 12477811.
6. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269-80. 10.1084/jem.191.8.1269, 2193131, 10770795.
7. Norris S, Collins C, Doherty DG, Smith F, McEntee G, Traynor O, Nolan N, Hegarty J, O'Farrelly C. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998, 28:84-90.
8. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-56. 10.1016/j.coi.2006.03.017, 16616472.
9. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-8. 10.1016/S0092-8674(00)80856-9, 10850488.
10. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, Fu JL, Shi F, Shi M, Wang HF, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010, 51:81-91.
11. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol 2010, 30:546-55. 10.1007/s10875-010-9416-3, 20393789.
12. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-47.
13. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-41. 10.1038/ni1261, 1618871, 16200068.
14. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-32. 10.1038/ni1254, 16200070.
15. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-7. 10.1038/nri1032, 12658273.
16. Reiner SL. Development in motion: helper T cells at work. Cell 2007, 129:33-6. 10.1016/j.cell.2007.03.019, 17418783.
17. Yasumi Y, Takikawa Y, Endo R, Suzuki K. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res 2007, 37:248-54. 10.1111/j.1872-034X.2007.00040.x, 17397512.
18. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-76. 10.1016/j.immuni.2004.08.018, 15485625.
19. Li J, Wu W, Peng G, Chen F, Bai M, Zheng M, Chen Z. HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol 2010,
20. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, O'Farrelly C, Mills KH. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 2008, 181:4485-94.
21. Zhou L, Lopes JE, Chong MM, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-40. 10.1038/nature06878, 2597437, 18368049.
22. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-8. 10.1038/nature04753, 16648838.
23. Jaffar Z, Ferrini ME, Girtsman TA, Roberts K. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur J Immunol 2009, 39:3307-14. 10.1002/eji.200939498, 2849980, 19830731.
24. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-41. 10.1016/j.immuni.2005.01.016, 15780990.
25. Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003, 33:3473-83. 10.1002/eji.200323966, 14635058.
26. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, Blum HE, von Weizsacker F, Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005, 79:7860-7. 10.1128/JVI.79.12.7860-7867.2005, 1143651, 15919940.
27. Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005, 79:3322-8. 10.1128/JVI.79.6.3322-3328.2005, 1075696, 15731226.
28. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137-40.
29. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009, 3:269-82. 10.1007/s12072-008-9106-x, 2712314, 19669378.
30. Kamath P. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470. 10.1053/jhep.2001.22172, 11172350.